Oscar Health
OSCR
$31.89
-4.72%
Oscar Health, Inc. is a technology-driven health insurance company that sells individual and family health plans, primarily through the federal and state ACA marketplaces, and licenses its full-stack technology platform to other payers. It operates as a single segment but positions itself as a differentiated, tech-enabled challenger in the managed care industry, competing against far larger incumbents like UnitedHealth, Centene, and CVS/Aetna through a member-centric digital experience and proprietary claims and care infrastructure. The current investor narrative centers on a dramatic margin turnaround: after a loss-making 2025, Oscar has swung to substantial profitability in the first half of 2026, prompting management to raise its 2026 operating earnings outlook, and the stock has re-rated sharply higher. Debate now hinges on whether this profitability is durable given ACA subsidy policy uncertainty, medical cost trends, and second-half headwinds flagged in recent coverage, with analysts split between those who see a structural earnings inflection and those who view the rally as pricing in an overly optimistic scenario.…
OSCR
Oscar Health
$31.89
Related headlines
Investment Opinion: Should I buy OSCR Today?
The synthesized recommendation is Hold. Oscar Health has shown a remarkable turnaround with explosive revenue growth and a swing to profitability, but the sustainability of these margins is unproven and the stock has already rallied 113% YTD. The analyst consensus is Hold with an average target of $36.40, implying 14.1% upside, but the wide target range ($27-$49) and mixed recent ratings reflect low conviction. The core thesis is that the company has turned a corner, but investors should wait for more evidence of durable profitability before committing new capital.
Supporting evidence includes: 1) Revenue growth of 70.4% YoY in Q2 2026, far above industry norms; 2) Forward PE of 14.36x, in line with peers despite superior growth; 3) Q2 2026 net income of $361.8 million and operating margin of 7.85%, a dramatic improvement from negative margins; 4) Free cash flow TTM of $4.33 billion and cash of $4.05 billion, providing ample liquidity. The PS ratio of 0.32x is near the low end of its historical range, suggesting the market is not pricing in sustained profitability.
Key risks that could invalidate the thesis include: 1) Margin compression from second-half headwinds or unfavorable medical cost trends; 2) ACA subsidy policy changes that reduce membership or pricing; 3) Competitive pressure from larger payers. The rating would upgrade to Buy if the company demonstrates sustained margin expansion (e.g., net margin above 10% for two consecutive quarters) and revenue growth remains above 30%. It would downgrade to Sell if margins compress significantly (e.g., net margin below 5%) or if ACA subsidies are materially reduced. Relative to its history and peers, the stock appears fairly valued to slightly undervalued on a forward earnings basis, but the risk/reward is balanced given the recent rally.
Sign up to view all
OSCR 12-Month Price Forecast
Oscar Health presents a compelling turnaround story with explosive revenue growth and a dramatic swing to profitability, but the sustainability of these margins is uncertain. The stock has already rallied 113% YTD and trades near its 52-week high, leaving little room for disappointment. The analyst consensus is Hold with a target of $36.40, implying modest upside. We would upgrade to bullish if the company demonstrates sustained margin expansion (e.g., net margin above 10% for two consecutive quarters) and revenue growth remains above 30%. We would downgrade to bearish if margins compress significantly or if ACA subsidies are materially reduced. Given the balanced risk/reward, a neutral stance is appropriate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Oscar Health's 12-month outlook, with a consensus price target around $36.40 and implied upside of +14.1% versus the current price.
Average Target
$36.40
0 analysts
Implied Upside
+14.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$27 - $49
Analyst target range
Ten analysts cover Oscar Health, with a consensus recommendation of "hold" (mean rating of 2.82 on a scale where lower is more bullish) and an average target price of $36.40, implying roughly 14.1% upside from the current $31.89. The distribution skews cautious — recent actions from Raymond James (Outperform), Barclays (Overweight), Stephens (Equal Weight), Baird (Neutral), UBS (Neutral), and B of A (Underperform) show a split between bulls and skeptics, with no clear upgrade momentum. The consensus leans neutral-to-cautiously-bullish, reflecting appreciation of the earnings turnaround but concern about sustainability.
The target range is wide, from a low of $27.00 (about 15.3% downside) to a high of $49.00 (about 53.6% upside), signaling meaningful disagreement about the company's trajectory. The high target likely assumes durable margin expansion, continued membership growth, and multiple re-rating as profitability is proven, while the low target prices in margin compression from second-half headwinds, ACA subsidy risk, and competitive pressure from larger payers. The wide spread — a $22 range — indicates high uncertainty and low conviction, consistent with a stock whose beta of 2.469 and 51.71% max drawdown make it a high-risk, high-reward name; the consensus EPS estimate of $3.94 and revenue estimate of $32.47 billion underscore that analysts expect strong full-year results, but the hold rating suggests they want more evidence before turning constructive.
Drowning in data?
Find the real signal!
Bulls vs Bears: OSCR Investment Factors
The bull case rests on Oscar's explosive revenue growth (70.4% YoY), dramatic profitability inflection (Q2 net income of $361.8 million), strong cash flow, and attractive forward valuation (14.36x forward PE). The bear case centers on the durability of these margins given ACA subsidy risk, second-half headwinds, and intense competition from larger payers. Currently, the bull evidence appears stronger given the recent earnings momentum and raised guidance, but the stock's high beta (2.469) and 51.71% max drawdown underscore the risks. The single most important tension is whether the current margin levels are sustainable or a temporary peak; if margins hold, the stock could re-rate further, but if they compress, the rally may reverse sharply.
Bullish
- Explosive revenue growth: Q2 2026 revenue surged 70.4% YoY to $4.88 billion, following Q1 2026 revenue of $4.65 billion (up 52.5% YoY). This far outpaces typical single-digit managed care growth, indicating significant market share gains in the ACA individual market.
- Dramatic profitability inflection: Q2 2026 net income was $361.8 million (7.4% net margin) and Q1 2026 net income was $679.0 million (14.6% net margin), a stark reversal from losses of $352.6 million in Q4 2025 and $228.4 million in Q2 2025. The company has swung to substantial profitability in just two quarters.
- Strong cash flow and liquidity: Free cash flow TTM is $4.33 billion, operating cash flow was $2.05 billion in Q2 2026, and cash stood at $4.05 billion. This provides ample liquidity to fund growth and absorb potential headwinds.
- Attractive forward valuation: Forward PE of 14.36x on consensus EPS of $3.94 is in line with large-cap managed care peers despite Oscar's 70% revenue growth. The PS ratio of 0.32x is near the low end of its historical range (0.51x to 7.83x), suggesting the market is not extrapolating current margins.
Bearish
- Margin durability concerns: Q1 2026's 14.6% net margin benefited from favorable seasonality and reserve development, and recent coverage flags second-half headwinds. The Q2 operating margin of 7.85% may compress, and the company's ability to sustain profitability is unproven.
- ACA subsidy policy risk: Oscar's business is concentrated in ACA marketplaces, and subsidy policy uncertainty could impact membership and pricing. Any reduction in subsidies could pressure enrollment and margins, given the company's focus on individual and family plans.
- High volatility and drawdown risk: Beta of 2.469 and a max drawdown of 51.71% over the past year highlight extreme sensitivity to market and sector sentiment. The stock is up 113% YTD and near its 52-week high, leaving little margin for error.
- Hold consensus with wide target range: The consensus recommendation is 'hold' (mean rating 2.82) with a wide target range from $27 to $49, indicating low conviction. Recent actions include B of A (Underperform) and UBS (Neutral), suggesting skepticism about sustainability.
OSCR Technical Analysis
Oscar Health is in a powerful, sustained uptrend, with the stock up 51.64% over the past year and an extraordinary 113.03% year-to-date, massively outperforming the S&P 500's 15.53% and 11.93% respective gains. At a current price of $31.89, the stock sits at roughly 87.5% of its 52-week range (low of $10.69, high of $35.01), positioning it near the upper end of its annual band. This near-high positioning signals strong momentum but also leaves little margin for error, as the stock has already priced in a great deal of good news and is vulnerable to profit-taking near resistance. The 51.71% max drawdown over the period underscores how violently this name can reverse when sentiment shifts.
Short-term momentum has decelerated and diverged from the longer-term trend: the stock is down 1.39% over the past month and fell 4.72% in the latest session alone (from a previous close of $33.47 to $31.89), even as it remains up 9.59% over three months and 101.96% over six months. This divergence — a flat-to-negative one-month trend against a triple-digit six-month gain — suggests the rally is consolidating rather than reversing, but the sharp single-day drop and a relative strength reading of -2.61 versus the S&P over the past month indicate near-term underperformance and fading buying pressure. With a beta of 2.469, moves of this magnitude are characteristic of the stock's high sensitivity to market and sector sentiment, and the 3.02 short ratio implies short sellers are not aggressively pressing but remain a latent force.
Key technical levels are well defined: support sits near the 52-week low of $10.69, with intermediate support likely around the $28-$29 area where the stock consolidated in July and September, while resistance is the 52-week high of $35.01, just above the recent $34.32 peak. A breakout above $35.01 would confirm the uptrend and likely invite momentum buyers, whereas a breakdown below $28 would signal a deeper mean-reversion move toward the mid-$20s. The beta of 2.469 means the stock is roughly 2.5 times as volatile as the market, which demands smaller position sizing and wider stops; combined with a 51.71% max drawdown, risk management is paramount despite the strong trend.
Beta
2.47
2.47x market volatility
Max Drawdown
-51.7%
Largest decline past year
52-Week Range
$11-$35
Price range past year
Annual Return
+51.6%
Cumulative gain past year
| Period | OSCR Return | S&P 500 |
|---|---|---|
| 1m | -1.4% | +0.2% |
| 3m | +9.6% | +2.9% |
| 6m | +102.0% | +8.4% |
| 1y | +51.6% | +14.9% |
| ytd | +113.0% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OSCR Fundamental Analysis
Revenue growth is explosive and accelerating: Q2 2026 revenue reached $4.88 billion, up 70.4% year-over-year from $2.86 billion in Q2 2025, following Q1 2026 revenue of $4.65 billion versus $3.05 billion a year earlier. The multi-quarter trajectory shows a clear step-up — quarterly revenue has climbed from $2.81 billion in Q4 2025 to $4.65 billion in Q1 2026 and $4.88 billion in Q2 2026 — reflecting both membership growth and premium rate increases. This pace of growth, far above typical single-digit managed care industry growth, implies Oscar is taking meaningful share in the ACA individual market, though the sustainability of such growth depends heavily on subsidy policy and marketplace enrollment dynamics.
Profitability has inflected dramatically: Q2 2026 net income was $361.8 million (a 7.41% net margin) and Q1 2026 net income was $679.0 million (14.61% net margin), a stark reversal from losses of $352.6 million in Q4 2025 and $228.4 million in Q2 2025. The Q2 2026 operating margin of 7.85% and EBITDA of $393.8 million compare favorably to the deeply negative margins of the prior year, and the reported gross margin of 14.38% (noting the Q2 income statement's 100% gross margin reflects a classification quirk where cost of revenue is zero) is consistent with insurance economics where medical costs dominate. The key question is durability: Q1's 14.61% net margin benefited from favorable seasonality and reserve development, and the second-half headwinds cited in recent coverage suggest margins will compress from these peaks.
Balance sheet and cash flow metrics are strong but require context: free cash flow TTM is $4.33 billion, operating cash flow was $2.05 billion in Q2 2026, and cash at period end stood at $4.05 billion, giving the company ample liquidity. The debt-to-equity ratio of 0.44 is moderate, and a current ratio of 0.95 is slightly below 1.0 — typical for insurers that hold premiums payable as liabilities — while ROE of -45.33% reflects the trailing twelve-month loss from 2025 even as recent quarters are strongly profitable. The Q2 2026 historical ratios show ROE of 17.63% and ROA of 3.22%, indicating the underlying business is now generating solid returns; the negative headline ROE is a lagging artifact, and the interest coverage ratio of 81.3x confirms minimal financial stress.
Quarterly Revenue
$4.9B
2026-06
Revenue YoY Growth
+70.4%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OSCR Overvalued?
Because trailing net income is negative (EPS of -$0.12, trailing PE of -8.50x), the PE ratio is not meaningful, so the PS ratio is the appropriate primary metric; at 0.32x sales, Oscar trades at a very low multiple of revenue, reflecting the thin-margin nature of health insurance. The forward PE of 14.36x against consensus EPS of $3.94 is the more informative signal: it implies the market expects a full-year 2026 profit and prices the stock at a reasonable earnings multiple for a company growing revenue at 70%, suggesting the gap between trailing losses and forward profits is the core of the investment thesis. The PEG ratio of 0.005 is distorted by the near-zero earnings base and should be disregarded.
Peer comparison is constrained by the absence of a supplied industry-average multiple, but contextually Oscar's 0.32x PS is well below the 1x-plus multiples typical of managed care peers and far below software-like valuations, consistent with its low-margin insurance model; its 3.86x price-to-book is elevated relative to historical insurer norms. The forward PE of 14.36x is broadly in line with large-cap managed care peers trading in the low-to-mid teens, implying the market is not awarding Oscar a growth premium despite its far faster revenue growth — a potential value argument, or a reflection of skepticism about margin durability and ACA policy risk. The EV/sales of 0.147x and negative EV/EBITDA of -3.65x (trailing) further highlight how trailing figures understate the forward earnings power.
Historically, Oscar's PS ratio has ranged from roughly 0.51x (Q4 2022) to 7.83x (Q3 2021), and the current 0.32x is near the low end of that band, while the historical PE has swung wildly from negative to single digits. The Q2 2026 historical PE of 5.94x and price-to-book of 4.20x show the stock has re-rated from the depressed levels of 2025, but on a sales basis it remains cheap relative to its own history. This suggests the market is pricing in continued profitability but not extrapolating the current margin peak, leaving room for re-rating if earnings prove durable — or for further compression if ACA headwinds materialize.
PE
-8.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~6x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-3.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Oscar's profitability is recent and may not be durable: Q1 2026 net margin of 14.6% benefited from favorable seasonality and reserve development, and Q2 net margin declined to 7.4%. The company's debt-to-equity ratio of 0.44 is moderate, but a current ratio of 0.95 is slightly below 1.0, typical for insurers but leaving little buffer. Revenue is highly concentrated in ACA individual plans, making the company vulnerable to policy changes. Additionally, the trailing ROE of -45.33% reflects the 2025 losses, and while recent quarters show positive ROE (17.63% in Q2 2026), the sustainability of these returns is uncertain.
Market and competitive risks are pronounced. Oscar trades at a forward PE of 14.36x, in line with peers, but its PS ratio of 0.32x is near the low end of its historical range, suggesting the market is skeptical about margin durability. The stock's beta of 2.469 means it is highly sensitive to market swings, and a sector rotation away from growth or healthcare could hit it hard. Competitive pressure from UnitedHealth, Centene, and CVS/Aetna is intense, and these larger players have greater scale and pricing power. Recent CMS boosts to Medicare Advantage payments may benefit larger peers more, potentially widening the competitive gap. ACA subsidy policy uncertainty remains a key overhang.
Worst-case scenario: A combination of margin compression from unfavorable medical cost trends, a reduction in ACA subsidies, and increased competition could trigger a sharp sell-off. The stock could fall to its 52-week low of $10.69, representing a 66.5% decline from the current $31.89. Even a retracement to the analyst low target of $27.00 would imply a 15.3% loss. Given the max drawdown of 51.71% over the past year, a decline of 50% or more is plausible in a adverse scenario, especially with the high beta amplifying market moves.
FAQ
The key risks include: 1) Margin durability – Q1 2026's 14.6% net margin may not be sustainable, and second-half headwinds could compress margins; 2) ACA subsidy policy risk – changes could reduce membership and pricing; 3) Competitive pressure – larger payers like UnitedHealth and Centene have greater scale and may respond aggressively; 4) High volatility – beta of 2.469 and max drawdown of 51.71% mean the stock can fall sharply in adverse market conditions. The most severe risk is a combination of margin compression and subsidy cuts, which could drive the stock toward its 52-week low of $10.69.
Our 12-month forecast has three scenarios: Bull (25% probability) with a target range of $45-$49, assuming sustained margin expansion and analyst upgrades; Base (50% probability) with a target range of $34-$38, assuming moderate margin compression but continued revenue growth; Bear (25% probability) with a target range of $27-$30, assuming margin compression and ACA subsidy headwinds. The base case is most likely, aligning with the analyst average target of $36.40. The key assumption is that Oscar maintains net margins in the 5-8% range for the remainder of 2026.
OSCR appears fairly valued to slightly undervalued on a forward basis. The forward PE of 14.36x is in line with large-cap managed care peers despite Oscar's much faster revenue growth, suggesting the market is not awarding a growth premium. The PS ratio of 0.32x is near the low end of its historical range (0.51x to 7.83x), indicating skepticism about margin durability. However, the trailing PE is negative due to 2025 losses, and the price-to-book ratio of 3.86x is elevated relative to insurer norms. Overall, the valuation implies the market expects profitability to continue but not to reach the peak margins seen in Q1 2026.
OSCR is a high-risk, high-reward stock that may be suitable for risk-tolerant investors. The company has shown explosive revenue growth (70.4% YoY in Q2 2026) and a dramatic swing to profitability (Q2 net income of $361.8 million), but the sustainability of these margins is uncertain. The stock trades at a forward PE of 14.36x, in line with peers, and the analyst average target of $36.40 implies 14.1% upside. However, the high beta (2.469) and max drawdown (51.71%) mean significant volatility. A good buy for those who believe in the long-term ACA market opportunity and can tolerate short-term swings, but not for conservative investors.
OSCR is more suitable for long-term, risk-tolerant investors than short-term traders. The company is in a growth phase with volatile earnings and no dividend, and its beta of 2.469 makes it prone to sharp swings. The profitability turnaround is recent and needs to be proven over multiple quarters. A minimum holding period of 2-3 years is recommended to ride out volatility and allow the company to demonstrate sustainable margins. Short-term trading could be profitable given the high volatility, but it requires active risk management and timing skill.
